A phase I clinical and pharmacological study of oral 9- nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 36-44

  Verschraegen, Claire F ^b   Natelson, Ethan A ^a   Giovanella, Beppino C ^a   Kavanagh, John J ^b   Kudelka, Andrzej P ^b   Freedman, Ralph S ^a   Edwards, Creighton L ^a   Ende, Karen ^a   Stehlin, John S ^a  

^a St Joseph's Medical Center Houston   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Anemia; Anorexia; Cystitis; Myelosuppression; Nausea; Neutropenia; Thrombocytopenia

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; RUBITECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CYSTITIS; DERMATITIS; DIARRHEA; DRUG FORMULATION; DRUG METABOLISM; HUMAN; IMMUNE DEFICIENCY; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0031909978     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00004     Document Type: Article

References (39)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97.
2. Wall ME, Wani MC, Cooke, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888-90.
3. Wall ME, Wani MC. Chemistry and antitumor activities of camptothecins. In: Potmesil M, Khon KW, eds. DNA topoisomerases in cancer. New York: Oxford University Press 1991: 93-102.
4. Jaxel C, Kohn KW, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989; 49: 1465-9.
5. Liu LF. DNA topoisomerases - enzymes that catalyze the breaking and rejoining of DNA. Annu Rev Biochem 1983; 15: 19-24.
6. Liu LF, D'Arpa P. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Import Adv Oncol 1992; 79-89.
7. Hsiang YH, Liu LF, Wall ME, et al. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989; 49: 4385-9.
8. Schneider E, Hsiang YH, Liu L. DNA topoisomerase as anticancer drug targets. Adv Pharmacol 1990; 21: 149-83.
9. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972; 32: 2643-50.
10. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834-6.
11. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-81.
12. Huang R, Tsuda H, Liang J, et al. Topoisomerase I inhibitors, irinotecan hydrochloride and SN-38 induce apoptosis in leukemia cell lines. Proc Am Ass Cancer Res 1994; 35: A5.
13. Hertzberg RP, Caranfa MJ, Holdem KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1982; 32: 15-9.
14. Burke TG, Mi Z. Preferential binding of carboxylate form of camptothecin by human serum albumin. Anal Biochem 1993; 212: 285-7.
15. Mi Z, Burke TG. Marked interspecies variations concerning interactions of camptothecin with serum albumin. Biochem 1994; 33: 12540-5.
16. Mi Z, Burke TG. Marked interspecies variations concerning interactions of camptothecin analogues with serum albumin. Proc Am Ass Cancer Res 1995; 36: 444.
17. Hinz HR, Harris NJ, Natelson EA, et al. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res 1994; 52: 3096-100.
18. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
19. Giovanella BC, Hinz HR, Kozielski AJ, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res 1991; 51: 3052-5.
20. Stehlin JS, Natelson EA, Hinz HR, et al. Phase I clinical trial and pharmacokinetics results with oral administration of 20(S)-camptothecin. In: Potmesil M, Pinedo H, eds. Camptothecins, new anticancer agents. Boca Raton, FL: CRC Press 1995: 59-65.
21. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
22. WHO handbook for reporting results of cancer treatment. Geneva: WHO 1979: 48.
23. Verschraegen C, Harris N, Steger M, Kavanagh J, Kudelka A, Giovanella B. Pharmacology study of multiple doses of 9-nitrocamptothecin. Proc Am Ass Cancer Res 1997; 38: A709.
24. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
25. Creemers GJ, Beijnen JH, Planting AS, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9.
26. Hochster H, Speyer J, Wadler S, et al. Phase II study of topotecan 21-day infusion in platinum-treated ovarian cancer: a highly active regimen. Proc Am Soc Clin Oncol 1996; 15: 285.
27. Creemers GJ, Schellens JH, Beijnen JH, et al. Bioavailability of oral topotecan. Proc Am Soc Clin Oncol 1994; 13: 324.
28. Kuhn J, Rizzo J, Eckardt J, et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995; 14: A1538.
29. Kudelka A, Tresukosol D, Edwards C, et al. Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-7.
30. Kunimito T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10(4-(1-Piperidino)-1-Piperidino) carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-7.
31. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996; 1: 21-6.
32. Chabot G, De Forni M, Abigerges D, et al. Clinical trials and pharmacology studies of CPT-11 and its active metabolite SN-38 in France: preliminary pharmacokinetic-pharmacodynamic relationships. In: Potmesil M, Pinedo H, eds. Camptothecins, new anticancer agents. Boca Raton, FL: CRC Press 1995: 83-92.
33. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5.
34. Rubin E, Wood V, Bharti A, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995; 12: 269-76.
35. Takimoto CH, Dahut W, Harold N, et al. A phase I trial of prolonged infusion of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Soc Clin Oncol 1996; 15: A1554.
36. Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dis 1992; 20: 706-12.
37. Kaneda N, Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 1990; 50: 1721-5.
38. Pantazis P, Harris N, Mendoza J, et al. Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur J Haematol 1994; 53: 246-8.
39. Chabot G, Gouyette A, Bissery M. Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan and active metabolite SN-38 in mice. Proc Am Ass Cancer Res 1994; 35: A2576.